This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The findings of the DeLLphi-304 study demonstrated improved OS of tarlatamab compared with single-agent chemotherapy (median OS [mOS], 13.6 The updated definition for HRMM is increasingly important as there is an increased focus on how to improve outcomes for patients with HRMM, functional HRMM, and true extramedullary disease.
SHOW MORE Nivolumab (Opdivo) and chemotherapy demonstrated an overall survival benefit at 5 years, affirming its role as a standard of care option. The CheckMate 816 trial showed a high pathological complete response rate without increased adverse events, supporting nivolumab as a standard treatment.
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.
Study Overview Researchers conducted a retrospective chart review of 80 patients aged 12 or older within Intermountain Health who were diagnosed with asthma between December 2022 and December 2023. To ensure continuity of care, patients included had seen a primary care provider both in the year prior to and following their diagnosis.
Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.
Results American Oncology Network (AON) Pharmacy collected data on waste and cost avoidance from February 2023 to September 2023. If a discrepancy is found, the pharmacy nurses will hold the shipment, and a clinical intervention will be communicated to the provider. During this time frame, the pharmacy documented 152 interventions.
From 2003 to 2023, 943 drugs were approved through the 505(b)(2) pathway. As of January 1, 2023, CMS has begun issuing unique J-codes to 505(b)(2) drugs dating back to 2003. “In However, 505(b)(2) drugs have been available since the 1980s.
Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. The infection risks are a little different.
Clinical Applications and Economic Impacts Biologics have significantly impacted cancer therapies by targeting cancer cells more specifically and reducing adverse events compared with traditional chemotherapy, Darkow noted. billion worth in savings in 2023 and $36 billion since the first biosimilar entered the market in 2015.
A man aged 55 years with metastatic colorectal cancer was initiated on a standard fluoropyrimidine-based chemotherapy regimen. Within a week, he developed severe neutropenia, gastrointestinal shutdown, and septic complications requiring admission to the intensive care unit.
Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.
They have a team of highly skilled distribution professionals who can juggle efficacy and safety checks along with compounding as if they were conductors of a world-class symphony. We need people to coordinate and track prior authorizations, write persuasive appeal letters, and keep patients updated.
Vitamin D supplementation increased 25-hydroxyvitamin-D levels significantly, suggesting a potential role in enhancing chemotherapy effectiveness. The study's findings support further research with larger samples to explore vitamin D's impact on chemotherapy and breast cancer remission likelihood.
Although improved clinical outcomes with the addition of chemotherapy to ICI have been recorded for some patients, there is ongoing research to understand how prognostic factors (eg, smoking history, tumor histology, performance status) can provide some predictive values for patient response to ICI therapy. months) and 6.4 months).
Development Trends: Oncology at the Forefront Gene therapy currently ranks third among therapeutic focus areas, with 2151 compounds in development in 2024 ( Figure ). 6 Chimeric antigen receptor (CAR) cell therapies ranked 10th with 795 candidates, holding steady from 2023.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!
Eligible patients include adults (≥ 18 years) diagnosed with CML receiving imatinib as first-line therapy for more than 1 month between 2008 and 2023. Materials and Methods This retrospective observational study utilized the Carolina Data Warehouse for Health electronic health record (EHR) database.
So I think the study really showed the benefit of remote clinical monitoring after starting chemotherapy. It frees up appointment slots for patients who need urgent care and helps streamline the process for new patients. Przespolewski : Pharmacists play a large role in managing drug shortages, especially those on the front lines.
Yes, we currently have antibody-drug conjugates that are conjugated to a cytotoxic chemotherapy. So are there oncogenic proteins that we can actually target that we couldn’t traditionally target with just a small molecule inhibitor? We look at ADCs. Unfortunately, these drugs are quite toxic.
Around late 2023, a friend was diagnosed with metastatic colorectal cancer at 46 years old. After learning of his diagnosis, our relationship shifted from small talk at school events to detailed discussions in an infusion center setting about chemotherapy, immunotherapy, clinical trials, alternative medicines, and anticipated adverse effects.
Additionally, patients may have received prior chemotherapy for advanced disease. Updated October 30, 2023. Additionally, taletrectinib was granted priority review, breakthrough designation, and orphan drug designation for this indication. Accessed June 11, 2025. ClinicalTrials.gov identifier: NCT04395677. Accessed June 11, 2025.
Updated March 20, 2023. Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. But doing so requires a new kind of expertise that spans science, strategy, and systems thinking.
Benmelstobart (TQB2450; Chia Tai Tianqing Pharmaceutical Group Co, Ltd) in combination with chemotherapy followed by sequential combination with anlotinib (Catequentinib; Advenchen Laboratories) led to significant improvements in progression-free survival (PFS), with a manageable safety profile. months versus 7.79 months with tislelizumab.
TRE-515 Combined With a Radiopharmaceutical As a precision cancer treatment designed for adults with PSMA-positive mCRPC, lutetium Lu 177 vipivotide tetraxetan is used after individuals have undergone other treatments like androgen receptor pathway inhibition and taxane-based chemotherapy.
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Mok : Right now, we have a lot of chemotherapy being used, but there are many more novel treatments being studied, especially in earlier lines of treatment. Bispecifics are moving up in the lymphoma space, and these newer therapies may have some synergistic effects with chemotherapy. REFERENCES 1. Updated August 18, 2021.
I think it’ll be chemotherapy—maybe their cells being given outpatient—and then, as we hit their hardest time or their highest risk for either febrile neutropenia or mucositis or even some of the toxicities from the chemotherapy, we have them inpatient until we feel comfortable, and then transition it so that it could be all outpatient.
1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.
You can also try using oxytocin nasal spray that you can get prescribed and compounded by your compounding pharmacist, taking Epsom salt baths, or using essential oils like lavender and clary sage. [60] A practitioner will help assess individual patients to determine if or when breastfeeding is advised. [11]
1 Scientific evidence between January 1, 2016, and January 31, 2023, was included in the study. This was assessed by analyzing real-world pharmacoepidemiological data and conducting a systematic review and meta-analysis to further quantify this risk. Subscribe Now!
News All News FDA Updates Press Releases Media All Videos Digital Detail Independent Corner Insights Interviews MEDcast Medical World News Microsites Peer Exchange Perfect Consult Podcasts Practice Pearls Sponsored Webcast Student Voices Webinars/Webcasts Conferences Conference Coverage Conference Listing Publications Pharmacy Times Pharmacy Practice (..)
Datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc) received FDA approval for treatment of adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy.
Related Videos Related Content Advertisement June 9th 2025 Neoadjuvant Nivolumab With Chemotherapy Yields Significant Overall Survival Benefit in Resectable NSCLC Luke Halpern, Assistant Editor June 3rd 2025 S2. Subscribe Now!
Additionally, you will get to experience our hands-on workshops unveiling a step-by-step guide to build a hit discovery funnel and harnessing the latest computational tools to amplify your compound screening abilities. At BIO 2025 in Boston, editor-in-chief Jonah Comstock spoke with Dr Raza Bokhari, CEO of Medicus Pharma.
Additionally, in June 2023, the world’s largest radionuclide production facility of lutetium-177 opened in Germany. With alpha particles, you must be very careful how the drug is made to ensure that the compound remains stable between manufacturing and use. Recent advancements for radiopharmaceuticals in oncology include a $1.4
That compound (previously called TAK-580) was taken into a phase 1/2b trial in children with the brain cancer glioma before the Japanese drugmaker returned the rights after a review of its pipeline assets. The agreement is the second licensing deal for Day One that targets the MAPK pathway, which is implicated in a wide range of tumours.
The deal, expected to be completed by the end of 2023, will see Pfizer pay $229 per Seagen share in cash for a total of $43bn, the largest deal for the sector in the past three years. GlobalData analysts forecast the total revenue from Seagen products to be around $36bn from 2023 to 2028, with a 29.3%
Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.
On 8 May 2023, China-based Bliss Biopharmaceutical (BlissBio) announced a clinical trial collaboration with Eisai to develop BB-1701, an antibody-drug conjugate (ADC) for multiple cancer types. The agent is a human epidermal growth factor receptor 2 (HER2)-targeting ADC that utilises Eisai’s chemotherapy Halaven (eribulin) as its payload.
Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers, yet they can cause ototoxicity, permanent and irreversible hearing loss, which occurs in up to 50-60 percent of adult patients and 90 percent of paediatric patients who survive cancer. This control arm will provide natural history data.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content